T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
WAY
801
Waystar Holding Corp
WAY
$4.81B
| $52.8M | 0.01% |
1,611,445
+318,007
| +25% | +$11.3M |
|
802
Flex
FLEX
$45.9B
| $52.7M | 0.01% |
872,620
+246,152
| +39% | +$15.2M |
|
803
Pegasystems
PEGA
$5.51B
| $52.7M | 0.01% |
882,800
+414,817
| +89% | +$24.3M |
|
804
Unity
U
$20.2B
| $52.7M | 0.01% |
1,193,312
+429,124
| +56% | +$17.5M |
|
805
Spyre Therapeutics
SYRE
$8.98B
| $52.5M | 0.01% |
1,601,882
+981,262
| +158% | +$25.6M |
|
806
Regions Financial
RF
$27B
| $52.4M | 0.01% |
1,932,818
-345,083
| -15% | -$8.81M |
|
807
Arm
ARM
$298B
| $52.1M | 0.01% |
477,040
-46,374
| -9% | -$6.74M |
|
808
Sysco
SYY
$40B
| $51.9M | 0.01% |
704,518
+3,110
| +0.4% | +$237K |
|
809
Boyd Gaming
BYD
$6.05B
| $51.9M | 0.01% |
608,840
-59,291
| -9% | -$4.89M |
|
810
Otis Worldwide
OTIS
$27.8B
| $51.7M | 0.01% |
592,015
-7,942
| -1% | -$711K |
|
811
ON Semiconductor
ON
$31.8B
| $51.4M | 0.01% |
949,369
+215,350
| +29% | +$11M |
|
812
Laureate Education
LAUR
$5.15B
| $51.2M | 0.01% |
1,520,412
-300,007
| -16% | -$9.26M |
|
813
Commault Systems
CVLT
$6.26B
| $51.1M | 0.01% |
407,362
-304,402
| -43% | -$42.8M |
|
814
Fidelity National Information Services
FIS
$22.8B
| $50.8M | 0.01% |
764,983
+6,934
| +0.9% | +$457K |
|
815
Leidos
LDOS
$17.9B
| $50.8M | 0.01% |
281,463
+9,232
| +3% | +$1.75M |
|
816
Genpact
G
$5.78B
| $50.7M | 0.01% |
1,083,412
-65,456
| -6% | -$2.83M |
|
817
Iron Mountain
IRM
$37.7B
| $50.3M | 0.01% |
606,859
+11,264
| +2% | +$1.05M |
|
818
Arch Capital
ACGL
$33.5B
| $50.3M | 0.01% |
524,254
-89,738
| -15% | -$8.21M |
|
819
IDEAYA Biosciences
IDYA
$3.53B
| $50.1M | 0.01% |
1,449,145
+339,405
| +31% | +$10.8M |
|
|
CVSA
820
Covista Inc
CVSA
$4.49B
| $49.9M | 0.01% |
482,150
-8,350
| -2% | -$956K |
|
821
Teva Pharmaceuticals
TEVA
$42.6B
| $48.7M | 0.01% |
1,559,602
+1,050,901
| +207% | +$25.9M |
|
822
Gartner
IT
$11.6B
| $48.7M | 0.01% |
192,871
-178,021
| -48% | -$42.8M |
|
823
Vicor
VICR
$10.4B
| $48.2M | 0.01% |
439,820
+413,038
| +1,542% | +$35.1M |
|
|
GRMN
824
Garmin
GRMN
$60.2B
| $48.1M | 0.01% |
237,172
-1,417
| -0.6% | -$308K |
|
825
Mineralys Therapeutics
MLYS
$2.31B
| $48.1M | 0.01% |
1,325,120
+1,303,737
| +6,097% | +$52.3M |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.